Ibrutinib Therapy and Mycobacterium chelonae Skin and Soft Tissue Infection | Zendy

Khalid M Dousa | Zendy; Ahmed Babiker | Zendy; Daniel Van Aartsen | Zendy; Neel Shah | Zendy; Robert A. Bonomo | Zendy; John L. Johnson | Zendy; Marion Skalweit | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Ibrutinib Therapy and Mycobacterium chelonae Skin and Soft Tissue Infection

Author(s) -

Khalid M Dousa,

Ahmed Babiker,

Daniel Van Aartsen,

Neel Shah,

Robert A. Bonomo,

John L. Johnson,

Marion Skalweit

Publication year - 2018

Publication title -

open forum infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.546

H-Index - 35

ISSN - 2328-8957

DOI - 10.1093/ofid/ofy168

Subject(s) - mycobacterium chelonae , medicine , ibrutinib , pathogenic organism , soft tissue , mycobacterium avium complex , dermatology , mycobacterium , pathology , microbiology and biotechnology , leukemia , biology , tuberculosis , chronic lymphocytic leukemia

Ibrutinib is an irreversible inhibitor of Bruton's tyrosine kinase approved for the treatment of B-cell malignancies. There is growing concern about the risk of opportunistic infections following ibrutinib therapy. Herein, we describe the first case of skin and soft tissue infection in a patient receiving ibrutinib and recount the challenges in treating this infection.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research